A new drug application (NDA) and a biologics license application (BLA) have been resubmitted and accepted by the FDA for ...

During a live event, Sumanta K. Pal and other oncologists discuss the safety and efficacy of belzutifan for advanced renal ...

The sBLA is supported by results from the pivotal phase 3 TROPION-Breast02 clinical trial (NCT05374512), which evaluated the efficacy and safety of Dato-DXd compared with the investigator’s choice of ...

The key alterations sought are FGFR3 activating mutations or fusions/rearrangements (“susceptible” alterations), for potential use of the FGFR inhibitor erdafitinib (Balversa), and HER2 IHC expression ...

A significant portion of the clinical management for ADCs involves addressing payload-dependent toxicities, with interstitial lung disease (ILD) being a notable safety concern and potentially serious ...

A groundbreaking phase 2 trial explores a novel, chemotherapy-free immunotherapy for relapsed indolent B-cell lymphomas, aiming to enhance patient outcomes.

Recent trials reveal promising advancements in targeted therapies for chondrosarcomas and tenosynovial giant cell tumors.

Discover the latest advancements in pancreatic cancer treatment, including targeted therapies and next-generation sequencing, transforming patient care and outcomes.

QTX-2101, an oral arsenic trioxide, received FDA fast track designation for acute promyelocytic leukemia, aiming to simplify ...

Discover how antibody-drug conjugates (ADCs) are transforming treatment strategies for gastrointestinal cancers, enhancing ...

This opening segment establishes the clinical context for a 66 year old man with well differentiated, non functioning, ...

IFx-2.0, an innate immune agonist, targets resistance to immune checkpoint inhibitors in advanced cutaneous melanoma, receiving FDA orphan drug designation. Phase 1 trials showed IFx-2.0's safety and ...